Hypothesis

Morning exposure to high‑intensity, blue‑enriched dawn light (>1000 lux, 460‑480 nm) triggers a sustained ipRGC‑mediated activation of the AMPK‑SIRT1‑NAD+ axis, thereby priming cellular antioxidant defenses and mitochondrial respiration that offset the deleterious effects of evening blue‑light exposure on circadian health.

Mechanistic Rationale

1. ipRGC signaling to metabolic hubs – Intrinsically photosensitive retinal ganglion cells project not only to the suprachiasmatic nucleus but also to the intergeniculate leaflet and olivary pretectal nucleus, regions that influence autonomic output to peripheral tissues. Recent work shows that acute ipRGC activation can increase sympathetic tone to brown adipose tissue, raising cAMP and activating AMPK [1].

2. AMPK‑SIRT1‑NAD+ cascade – AMPK phosphorylation stimulates NAD+ biosynthesis via NAMPT, increasing SIRT1 deacetylase activity. SIRT1 then deacetylates PGC‑1α, enhancing mitochondrial biogenesis and upregulating antioxidant enzymes (SOD2, catalase). This creates a “metabolic shield” that reduces ROS accumulation later in the day.

3. Counteracting evening blue light – Evening blue‑light (<10 lux, red‑shifted) suppresses melatonin and elevates intracellular ROS in neurons and hepatocytes, a process linked to amyloid‑β aggregation and insulin resistance [3]. If the morning‑induced AMPK‑SIRT1 axis is already active, the heightened NAD+ pool can sustain SIRT1‑mediated deacetylation of clock proteins (BMAL1, PER2), preserving rhythm amplitude and limiting phase delays.

Testable Predictions

• Prediction 1: Participants receiving 30 min of dawn‑simulation light will show a 2‑fold increase in retinal ipRGC calcium flux (measured via pupillometry) and a concomitant rise in peripheral blood p‑AMPK (Thr172) within 30 min post‑exposure, relative to dim‑light controls.
• Prediction 2: The same group will exhibit elevated NAD+/NADH ratios and increased SIRT1 activity in isolated PBMCs at 2 h and 6 h after exposure.
• Prediction 3: When challenged with 2 h of evening blue‑light (≈200 lux, 480 nm) three hours after the morning session, the dawn‑light group will display attenuated melatonin suppression (<15 % vs >40 % in controls) and lower neuronal ROS (measured by MitoSOX in iPSC‑derived neurons).
• Prediction 4: Pharmacological blockade of melanopsin (e.g., intravitreal injection of AA‑93‑143) or genetic knockdown of ipRGCs in a murine model will abolish the dawn‑light‑induced p‑AMPK rise and erase the protective effect on evening blue‑light‑induced metabolic dysregulation.

Falsifiability

If dawn‑light exposure fails to produce a statistically significant increase in p‑AMPK or NAD+/NADH compared with matched dim‑light controls, or if ipRGC inhibition does not diminish the observed metabolic protective effects, the hypothesis would be refuted. Conversely, confirmation of the predicted molecular cascade would support a novel ipRGC‑driven metabolic priming mechanism that complements existing circadian entrainment models.